AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORTHOCELL LTD

1.335

+0.0100.75%

Volume:892.94K

Turnover:1.18M

Market Cap:323.04M

PE:-83.76

High:1.355

Open:1.340

Low:1.300

Close:1.325

Loading ...

Overview Company News Filings

Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir

THOMSON REUTERS

BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans

BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated

Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%

MT Newswires Live

Orthocell Ltd - Market Expansion of Remplir Will Be Accelerated Ahead of US FDA Clearance Expected in March/April 2025

THOMSON REUTERS

Orthocell Poised to Meet Fiscal 2025 Revenue Estimate; Euroz Hartley Says

MT Newswires Live

ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025

The Market Herald

Orthocell Logs Another Record Revenue in December 2024 Quarter; Shares Up 5%

MT Newswires Live

Those who invested in Orthocell (ASX:OCC) a year ago are up 235%

Simply Wall St.

Orthocell Files Premarket Application With US FDA for Nerve Repair Device; Shares Down 5%

MT Newswires Live

Orthocell Ltd-US FDA Application Submitted for Remplir as US Launch Nears

THOMSON REUTERS

Trump Advisers Explore Closing, Reorganizing Bank Regulators, Report Says

ASX Market Close: Index dives to three week low | December 12, 2024

The Market Herald

Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%

MT Newswires Live

Chris Judd’s Talk Ya Book: Orthocell building on ‘enormous potential’ with steady growth – and US push to come

The Market Herald

Orthocell Completes US Regulatory Study for Nerve Repair Product; Shares Hit All-Time High

MT Newswires Live

BRIEF-Orthocell Seeks Trading Halt

Orthocell Ltd - Seeks Trading Halt Pending Results of Regulatory Study Required for FDA Approval of Remplir

THOMSON REUTERS

Orthocell Taps Singaporean Distributor for Nerve Repair Device; Shares Hit New 52-Week High

MT Newswires Live

BUZZ-Australia's Orthocell hits more than 5-year high on Singapore expansion deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OCC.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":1.335,"timestamp":1747203120000,"preClose":1.325,"halted":0,"volume":892941,"delay":0,"nameEN":"ORTHOCELL LTD","floatShares":191252770,"shares":241976241,"eps":-0.015939,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"05-14 16:12:00 AEST","open":1.34,"high":1.355,"low":1.3,"amount":1183417,"amplitude":0.041509,"askPrice":1.335,"askSize":9675,"bidPrice":1.325,"bidSize":7484,"shortable":3,"etf":0,"ttmEps":-0.015939,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747267200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.325,"openAndCloseTimeList":[[1747180800000,1747202400000]],"volumeRatio":0.637777,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":191252770,"roa":"-20.32%","roe":"-29.77%","lyrEps":-0.035547,"volumeRatio":0.637777,"shares":241976241,"dividePrice":0,"high":1.355,"amplitude":0.041509,"preClose":1.325,"low":1.3,"week52Low":0.35,"pbRate":"16.45","psRate":"51.15","week52High":1.79,"institutionHeld":0,"latestPrice":1.335,"committee":-0.127688,"eps":-0.015939,"divideRate":0,"volume":892941,"delay":0,"ttmEps":-0.015939,"open":1.34,"prevYearClose":1.355,"prevWeekClose":1.38,"prevMonthClose":1.595,"prevQuarterClose":1.495,"fiveDayClose":1.48,"twentyDayClose":1.42,"sixtyDayClose":1.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508315673","title":"Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2508315673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508315673?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:01","pubTimestamp":1738533685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2505766845","title":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2505766845","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505766845?lang=en_us&edition=fundamental","pubTime":"2025-01-22 12:49","pubTimestamp":1737521354,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln  U.S. market commercially** Co expects approval in March/April 2025** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln** Stock rose 230.5% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nL3N3OI0BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2505753628","title":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505753628?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:31","pubTimestamp":1737509461,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be AcceleratedJan 22 (Reuters) - Orthocell Ltd OCC.AX:MARKET EXPANSION OF REMPLIR WILL BE ACCELERATED AHEAD OF US FDA CLEARANCE EXPECTED IN MARCH/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2505586757","title":"Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505586757","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505586757?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:17","pubTimestamp":1737508624,"startTime":"0","endTime":"0","summary":"Orthocell  is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.The firm's shares rallied 14% in early trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XKO.AU","XAO.AU","XJO.AU","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2505978067","title":"Orthocell Ltd - Market Expansion of Remplir Will Be Accelerated Ahead of US FDA Clearance Expected in March/April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505978067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505978067?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:59","pubTimestamp":1737496746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2504736439","title":"Orthocell Poised to Meet Fiscal 2025 Revenue Estimate; Euroz Hartley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2504736439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504736439?lang=en_us&edition=fundamental","pubTime":"2025-01-17 08:51","pubTimestamp":1737075081,"startTime":"0","endTime":"0","summary":"Orthocell  is on track to meet Euroz Hartley's fiscal 2025 revenue forecast of AU$8.8 million, following positive second-quarter results that met expectations, according to a Wednesday note from the financial services firm.The company reported a 9% quarter-on-quarter increase in revenue to AU$2.2 million, bringing first-half revenue to AU$4.2 million, up 29% year-on-year, Euroz Hartleys said.Euroz Hartleys noted that growth was driven by product launches, including Striate+ for dental bone repair and Remplir for nerve repair.Euroz Hartley believes that the upcoming US FDA approval of Orthocell's Remplir product, expected by April, will be a key catalyst for the company's growth. Approval would allow Remplir to enter the $1.6 billion US nerve repair market, and see a potential increase in the company's share price, it added.Euroz Hartleys maintained the company's hold rating and its price target of AU$0.97.Orthocell's shares slipped almost 1% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU"],"gpt_icon":1},{"id":"2501988077","title":"ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501988077","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501988077?lang=en_us&edition=fundamental","pubTime":"2025-01-08 10:28","pubTimestamp":1736303280,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.65% at 8,338 points in afternoon trade.Inflation edged upmore than expected, from2.1% to 2.3%. More importantly, trimmed mean inflation  came in at3.2%,still outside the RBA’s 2% to 3% target range.While consensus had shifted towards a 70% probability of a rate cut in February, some analysts don’t see this happening until later in the year.Materials has bounced back and has been the biggest winner, up 1.5%, followed by Financials, up 0.85%, and Health Care, up 0.75%.IT has lost the most ground, down 0.7%, followed by Real Estate and Telecommunication, both down 0.3%.Meeka Metalshas been up 10.5% on a breakthrough in its drilling program at St Anne’s within the Murchison Gold Project. The latest assays reveal bonanza-grade gold intersections, bolstering plans for an expanded Stage 1 open pit.Orthocell  has been up 5.6% after posting a third consecutive quarter of record revenue. The company reported a 46% increase in revenue to $2.21 million for the December ’24","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-inflation-higher-than-expected-as-miners-bounce-back-january-8-2025-2025-01-08/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","AVH.AU","BK7104","MEK.AU","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2501750433","title":"Orthocell Logs Another Record Revenue in December 2024 Quarter; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501750433","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501750433?lang=en_us&edition=fundamental","pubTime":"2025-01-08 08:25","pubTimestamp":1736295939,"startTime":"0","endTime":"0","summary":"Orthocell's  revenue climbed 46% to AU$2.2 million in the three months to December 2024 from AU$1.5 million in the year-earlier period, according to a Wednesday filing with the Australian bourse.Revenue was up 9% from AU$2 million in the three months to September 2024, marking a third consecutive quarter of record revenue.The regenerative medicine company attributed the increase to growth in existing markets for its Striate and Remplir products, per the filing. It anticipates the US Food and Drug Administration's approval of Remplir by March or April, enabling it to unlock a $1.6 billion nerve repair market.Orthocell's shares rose past 5% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU"],"gpt_icon":0},{"id":"2500952625","title":"Those who invested in Orthocell (ASX:OCC) a year ago are up 235%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500952625","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500952625?lang=en_us&edition=fundamental","pubTime":"2025-01-01 05:42","pubTimestamp":1735681333,"startTime":"0","endTime":"0","summary":"When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that is really flourishing, you can make more than 100%. Take, for example Orthocell Limited . Its share price is already up an impressive 235% in the last twelve months. It's also good to see the share price up 230% over the last quarter. Looking back further, the stock price is 168% higher than it was three years ago.Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.Given that Orthocell didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.Please note, the market returns quoted in this article reflect the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-orthocell-asx-occ-214213196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4020","BK7508","BK7067","OCC.AU","OCC"],"gpt_icon":0},{"id":"2492160494","title":"Orthocell Files Premarket Application With US FDA for Nerve Repair Device; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492160494","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492160494?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:32","pubTimestamp":1734571949,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a 510 application with the US Food and Drug Administration to sell its Remplir nerve repair device in the US market, according to a Thursday filing with the Australian bourse.The submission is based on a regulatory study of Remplir, which met all the endpoints and provided key data to support the application, the filing said.The 90-calendar day review process is expected to start between March and April 2025, with commercial distribution expected soon after, the filing said.Shares fell nearly 5% in midday trade Thursday.Price : $1.20, Change: $-0.06, Percent Change: -4.78%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","LU0345774631.USD","LU2238339852.HKD","BK7508","BK4125","OCC.AU","LU0426417589.USD","LU0994945656.USD","BK7067","AUD","LU1043141123.HKD"],"gpt_icon":0},{"id":"2492322150","title":"Orthocell Ltd-US FDA Application Submitted for Remplir as US Launch Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2492322150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492322150?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:02","pubTimestamp":1734559347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE6XLNCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2491370411","title":"Trump Advisers Explore Closing, Reorganizing Bank Regulators, Report Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2491370411","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491370411?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:48","pubTimestamp":1734101337,"startTime":"0","endTime":"0","summary":"The Trump transition team is exploringa range of financial sector reforms,The Wall Street Journal reported, including shutting theFederal Deposit Insurance Corp.Trump advisers have also also discussed plans to either combine or restructure the main federal bank regulators.Some of the ideas would require congressional action to enact.President-elect Donald Trump's transition team is exploring a range of financial sector reforms including shutting theFederal Deposit Insurance Corp. ,The Wall Street Journal reported.According to the Journal's report, Trump advisers and officials from his new Department of Government Efficiency , the advisory group co-chaired by Elon Musk and Vivek Ramaswamy, have in interviews with potential nominees to lead bank regulatory agencies asked whether the president-elect could abolish the watchdog.Trump advisers and potential nominees have also \"discussed plans to either combine or otherwise restructure\" the main federal bank regulators: the FDIC, the OCC and ","market":"us","thumbnail":"https://www.investopedia.com/thmb/THo8M96fg-Op5jRmPulyo22ItPA=/6240x4160/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187500032-4eae907561e74cefbb334b32ef093e70.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/THo8M96fg-Op5jRmPulyo22ItPA=/6240x4160/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187500032-4eae907561e74cefbb334b32ef093e70.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/trump-advisers-explore-closing-reorganizing-bank-regulators-report-says-8760978","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["OCC","US2Y.BOND","US30Y.BOND","OCC.AU","US3Y.BOND","BK7508","US10Y.BOND","BK4020","BK7067","US12M.BOND","US7Y.BOND","US5Y.BOND","US6M.BOND"],"gpt_icon":0},{"id":"2490419820","title":"ASX Market Close: Index dives to three week low | December 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490419820","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490419820?lang=en_us&edition=fundamental","pubTime":"2024-12-12 14:35","pubTimestamp":1733985300,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.28% at 8,330 points – finishing the session at a three-week low.Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened, and the Aussie dollar jumped in response. Analysts say the labour market poses minimal inflationary risk, but the RBA remains vigilant to prevent possible rebounds in underlying inflation.Economists have revised their predictions on rates, with the ANZ now predicting the first rate cut in May, while EY has predicted an initial cut in Q2.Industrials was the biggest loser, down 1.1%, followed by Telecommunication, down 1%, and Industrials, down 0.75%.Information Technology was the only substantive biggest winner, up 0.4%.Capstone Copper  closed up 1.6% after Citi initiated coverage with a “buy” rating, citing “positive earnings momentum” with a price target of $13.60. Feeding into Citi’s rating is its forecast of a US$10,000 per tonne copper price.Orthocell  closed up 4.0","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-dives-to-three-week-low-december-12-2024-2024-12-12/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7064","CSC.AU","BK7110","BK7143","PWR.AU","DOW.AU","BPT.AU","BK7142","OCC.AU","BK7507","BK7508","VNT.AU","BK7055","BK7067"],"gpt_icon":0},{"id":"2490810271","title":"Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490810271","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490810271?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:27","pubTimestamp":1733963272,"startTime":"0","endTime":"0","summary":"Orthocell  received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.The company's shares were up almost 5% in recent Thursday trade.Price : $1.05, Change: $+0.05, Percent Change: +4.50%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2238339852.HKD","LU0345774631.USD","LU1043141123.HKD","OCC.AU","BK4125","LU0994945656.USD","XKO.AU","XAO.AU","XJO.AU","BK7067","BK7508","LU0426412945.USD","AUD","LU0426417589.USD"],"gpt_icon":0},{"id":"2488133387","title":"Chris Judd’s Talk Ya Book: Orthocell building on ‘enormous potential’ with steady growth – and US push to come","url":"https://stock-news.laohu8.com/highlight/detail?id=2488133387","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488133387?lang=en_us&edition=fundamental","pubTime":"2024-12-04 12:54","pubTimestamp":1733288040,"startTime":"0","endTime":"0","summary":"OnChris Judd’sTalk Ya Book today, the AFL legend sat down with Orthocell Limited  chairman John Van Der Wielen to talk about the “overnight success” of the ASX-listed biotech company and its bright future.“We wanted to start at the top and get a strong board with the right expertise,” Mr Van Der Wielen told Mr Judd. These pickups included Professor Fiona Woods AM, the Hon. Kim Beazley, as well as Dr. Ravi Thadhani, the latter of whom is the executive vice president at Emory University which boasts 35,000 employees.Orthocell has two main products already in the chamber: A ‘grow your own bone’ dental scaffolding and Remplir, a nerve repair collagen preparing for a U.S. launch.Both have begun shipping in countries like Austria, Germany, and Singapore, with rollouts continuing in Australia and New Zealand – and Mr Van Der Wielen believes Orthocell’s global expansion can only sell confidence.In 2023, Chris joined the people he interviews in the world of funds management by creating the Ceru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/chris-judds-talk-ya-book-orthocell-building-on-enormous-potential-with-steady-growth-and-us-push-to-come-2024-12-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7503","BK4022","BK7508","CAR","OCC.AU","BK4230","BK7002","CAR.AU","BK7067"],"gpt_icon":0},{"id":"2488616300","title":"Orthocell Completes US Regulatory Study for Nerve Repair Product; Shares Hit All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2488616300","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488616300?lang=en_us&edition=fundamental","pubTime":"2024-12-02 09:13","pubTimestamp":1733102030,"startTime":"0","endTime":"0","summary":"Orthocell  completed its US Food and Drug Administration 510 regulatory study for Remplir, a collagen wrap product used in peripheral nerve repair, according to a Monday filing with the Australian bourse.The regulatory study is a crucial part of Orthocell's application with the US FDA for marketing clearance for Remplir, the filing said.The study met all endpoints, showing Remplir enables consistent and predictable recovery of upper arm and hand function following nerve repair. Clinical results showed 85% of nerve repairs with Remplir achieved functional muscle recovery 24 months post-treatment.The regenerative medicine company plans to submit its 510 application this month, with US FDA clearance expected in the first quarter of 2025.Remplir is already approved in Singapore, Australia, and New Zealand. The company plans to launch the product in Canada, the UK, Europe, and other ASEAN markets.Orthocell's shares rose nearly 10% in recent Monday trade and earlier hit an all-time high.Pric","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XAO.AU","XJO.AU","XKO.AU","AUD","BK7508","LU0426412945.USD","LU0345774631.USD","BK4125","LU0426417589.USD","LU2238339852.HKD","OCC.AU","LU1043141123.HKD","LU0994945656.USD"],"gpt_icon":0},{"id":"2487329769","title":"BRIEF-Orthocell Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2487329769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487329769?lang=en_us&edition=fundamental","pubTime":"2024-11-29 06:26","pubTimestamp":1732832762,"startTime":"0","endTime":"0","summary":"Nov 29 (Reuters) - Orthocell Ltd   :   * SEEKS TRADING HALT PENDING RESULTS OF REGULATORY STUDY REQUIRED FOR FDA APPROVAL OF REMPLIR Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2487329755","title":"Orthocell Ltd - Seeks Trading Halt Pending Results of Regulatory Study Required for FDA Approval of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2487329755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487329755?lang=en_us&edition=fundamental","pubTime":"2024-11-29 06:25","pubTimestamp":1732832745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241128:nFWN3MZ0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2486604298","title":"Orthocell Taps Singaporean Distributor for Nerve Repair Device; Shares Hit New 52-Week High","url":"https://stock-news.laohu8.com/highlight/detail?id=2486604298","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486604298?lang=en_us&edition=fundamental","pubTime":"2024-11-27 11:44","pubTimestamp":1732679054,"startTime":"0","endTime":"0","summary":"Orthocell  signed up Device Technologies Asia as its exclusive distributor for nerve repair damage device Remplir for the Singaporean market, according to a Wednesday filing with the Australian bourse.First sales from the new market are anticipated in the first quarter of 2025, the filing said.Device Technologies is currently the distributor of Remplir in Australia and New Zealand, as per the filing.The company's shares surged nearly 19% in recent Wednesday trade and earlier hit a new 52-week high.Price : $0.76, Change: $+0.12, Percent Change: +18.75%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345774631.USD","XJO.AU","AUD","LU0426412945.USD","OCC.AU","XKO.AU","LU1043141123.HKD","LU2238339852.HKD","BK4125","XAO.AU","BK7067","LU0994945656.USD","BK7508","LU0426417589.USD"],"gpt_icon":0},{"id":"2486486467","title":"BUZZ-Australia's Orthocell hits more than 5-year high on Singapore expansion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486486467","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486486467?lang=en_us&edition=fundamental","pubTime":"2024-11-27 10:49","pubTimestamp":1732675777,"startTime":"0","endTime":"0","summary":"** Orthocell    jumps as much as 21.1% to A$0.775, highest since May 9, 2019   ** Stock logs biggest intraday pct jump since early October   ** Biotech firm signs distributorship agreement with Singapore-based Device Technologies Asia for exclusive distribution of its nerve repair device Remplir   ** OCC expects first sales of the device in first quarter of 2025   ** Around 2.3 mln shares traded, 3.2x the 30-day avg   ** Stock up ~87% YTD ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":82,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[]}}